Table 4. Pharmacokinetic/ADME Properties of the Selected Compounds.

	pharmacokinetic/ADME properties
comp. no	GI absa	BBB permeantb	P-gpsubstratec	CYP1A2 inhibitord	CYP2C19 inhibitore	CYP2C9 inhibitorf	CYP2D6 inhibitorg	CYP3A4 inhibitorh	log Kpi
7	high	yes	no	yes	yes	yes	no	no	–5.44
8	high	yes	no	yes	yes	yes	no	no	–5.97
16	high	no	yes	no	yes	yes	no	yes	–5.71
17	low	no	yes	yes	yes	no	no	yes	–2.20
18	high	no	no	yes	yes	yes	no	yes	–5.19
19	high	no	no	yes	yes	yes	no	yes	–6.22
20	high	no	no	yes	yes	yes	no	yes	–6.54
21	high	no	no	no	yes	yes	no	yes	–7.06
22	high	no	yes	no	yes	yes	no	yes	–5.56
23	high	no	yes	no	yes	yes	no	yes	–5.61
24	high	no	yes	no	yes	yes	no	yes	–5.11
25	high	no	no	yes	yes	yes	no	yes	–6.08
26	high	no	no	yes	yes	yes	no	yes	–6.13
27	high	no	no	yes	yes	yes	no	yes	–5.62

^aGastrointestinal absorption.

^bBlood brain barrier permeant.

^cP-gp substrate.

^dCYP1A2: cytochrome P450 family 1 subfamily A member 2 (PDB: 2HI4).

^eCYP2C19: cytochrome P450 family 2 subfamily C member 19 (PDB: 4GQS).

^fCYP2C9: cytochrome P450 family 2 subfamily C member 9 (PDB: 1OG2).

^gCYP2D6: cytochrome P450 family 2 subfamily D member 6 (PDB: 5TFT).

^hCYP3A4: cytochrome P450 family 3 subfamily A member 4 (PDB: 4K9T).

ⁱSkin permeation in cm.